Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05734157
Other study ID # TP1109
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date February 17, 2022
Est. completion date September 1, 2025

Study information

Verified date February 2023
Source Chansu Vascular Technologies
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The CVT-SFA Trial investigates the inhibition of restenosis using the CVT Everolimus-coated PTA Catheter in the treatment of de-novo occluded/ stenotic or re-occluded/restenotic superficial femoral or popliteal arteries.


Description:

The CVT-SFA Trial is a prospective, multi-center, open, single arm study enrolling subjects with de-novo or post-PTA occluded/stenotic or re-occluded/ restenotic lesions (excluding in-stent lesions) ≤150mm in length in femoropopliteal arteries with reference vessel diameters of 4-6mm, receiving up to two (2) CVT Everolimus-coated PTA Catheters to establish blood flow and to maintain vessel patency.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 76
Est. completion date September 1, 2025
Est. primary completion date February 3, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Subject must be at least 18 years of age. 2. Subject provides written informed consent prior to any clinical investigation related procedure, as approved by the appropriate Ethics Committee of the respective clinical site. 3. Subject must agree to undergo all clinical investigation plan-required follow-up visits and examinations. 4. Subjects with symptomatic leg ischemia who do not respond favorably to Exercise Therapy or with symptoms that impact significantly daily life, requiring treatment of SFA or popliteal (P1 segment) artery. 5. De novo or restenotic lesion(s) >70% within the SFA and popliteal arteries in a single limb which are =3 cm and =15 cm in cumulative total length (by visual estimation). Lesion must be at least 2 cm from any stented area. 6. Subject is willing to comply with the required follow up visits, testing schedule and medication regimen. 7. Successful wire crossing of lesion. 8. Target vessel reference diameter =4 mm and =6 mm (by visual estimation). 9. Target lesion(s) can be treated with a maximum of two (2) CVT Everolimus-coated PTA Catheters. 10. At least one patent (less than 50% stenosis) tibio-peroneal run-off vessel confirmed by baseline angiography or prior MR angiography or CT angiography. 11. Life expectancy >1 year 12. Rutherford classification of 2, 3 or 4. Exclusion Criteria: 1. Pregnant or lactating females. 2. Co-existing clinically significant aneurismal disease of the abdominal aorta, iliac or popliteal arteries. 3. Significant gastrointestinal bleeding or any coagulopathy that would contraindicate the use of anti-platelet therapy. 4. Known intolerance to study medications, everolimus or contrast agents. 5. Doubts in the willingness or capability of the subject to allow follow-up examinations. 6. Subject is actively participating in another investigational device or drug study. 7. History of hemorrhagic stroke within 3 months of procedure. 8. Previous or planned surgical or interventional procedure within 30 days of index procedure. 9. Prior vascular surgery of the target lesion. 10. Lesion length is <3 cm or >15 cm or there is no normal proximal arterial segment in which duplex ultrasound velocity ratios can be measured. 11. Known inadequate distal outflow. 12. Significant inflow disease. 13. Acute or sub-acute thrombus in target vessel. 14. Use of adjunctive therapies (i.e. laser, atherectomy, cryoplasty, scoring/cutting balloons, brachytherapy, lithotripsy). 15. Outflow arteries (distal popliteal, anterior or posterior tibial or peroneal arteries) with significant lesions (= 50% stenosis) may not be treated during the same procedure. 16. Treatment of the contralateral limb during the same procedure or within 30 days of the study procedure. 17. Rutherford classification of 0, 1, 5 or 6 18. Presence of prohibitive calcification that precludes adequate PTA treatment. 19. Subjects held in custody in an institution by official or court order. 20. Subject is not covered by any medical insurance coverage.

Study Design


Intervention

Device:
Peripheral PTA with a drug coated balloon
Peripheral artery angioplasty

Locations

Country Name City State
France Polyclinique Les Fleurs Ollioules
France Hôpital Paris Saint Joseph Paris
France Hôpital Nord Laennec - CHU de Nantes Saint-Herblain
France Clinique Pasteur Toulouse
Germany Jüdisches Krankenhaus Berlin Berlin
Germany Vivantes Klinikum Neukölln Berlin
Germany DIAKO Krankenhaus Flensburg Flensburg
Germany Romed Klinikum Rosenheim Rosenheim

Sponsors (1)

Lead Sponsor Collaborator
Chansu Vascular Technologies

Countries where clinical trial is conducted

France,  Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Freedom of Major Adverse Event (MAE) rate Composite rate of cardiovascular death, index limb amputation and ischemia-driven target lesion revascularization (TLR). 6 months post-procedure
Primary Patency Freedom from restenosis as determined by duplex ultrasonography (DUS) (peak systolic velocity ratio (PSVR) =2.4 or =50% stenosis) and freedom from ischemia-driven target lesion revascularization (TLR). 6 months post procedure
Secondary Rate of MAE Composite rate of cardiovascular death, index limb amputation and ischemia-driven Target Lesion Revascularization (TLR). One year post-procedure
Secondary Patency Freedom from clinically driven TLR and duplex ultrasonography detected restenosis (ultrasound peak systolic velocity ratio = 2.4 or stenosis =50%) 12 months post procedure
See also
  Status Clinical Trial Phase
Completed NCT01947478 - MDT-2113 Drug-Eluting Balloon vs. Standard PTA for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery and/or Proximal Popliteal Artery N/A
Recruiting NCT03687983 - Safety and Efficacy Study of GoldenFlow Peripheral Stent System N/A
Completed NCT02720003 - A Single Arm Trial Evaluating the BARD Lutonix Drug-Coated Balloon (LTX DCB) for Treatment of Femoropopliteal Arteries N/A
Completed NCT02063672 - Lutonix® Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis N/A
Completed NCT01816412 - LEVANT Japan Clinical Trial Phase 2
Completed NCT01566461 - IN.PACT Admiral Drug-Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Superficial Femoral Artery (SFA) and Proximal Popliteal Artery (PPA) N/A
Completed NCT01412541 - Moxy Drug Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Femoropopliteal Arteries N/A
Recruiting NCT03683459 - Safety and Efficacy Study of FemFlow Drug-Eluting Peripheral Balloon Catheter N/A
Recruiting NCT03142347 - Remote Endarterectomy vs Remote Endarterectomy + Drug Coated Balloon (DCB) Angioplasty in Patients With the Femoral Artery Occlusive Disease N/A
Terminated NCT00810134 - Bypass or Thurpass for Superficial Femoral Artery Occlusion? Scandinavian Thurpass Study N/A
Completed NCT02013271 - Lutonix® DCB for Treatment of Long Lesions in Femoropopliteal Arteries
Completed NCT04343196 - Digital Variance Angiography in Diagnostic Angiographies for Effective Radiation Dose Reduction N/A
Terminated NCT02813577 - Lutonix Drug Coated Balloon for Treatment of Femoropopliteal Arteries in United States Females (CONFIRM) N/A
Completed NCT03844724 - Drug-eluting PTA Balloon Dilatation Catheter in the Treatment of Peripheral Artery Stenosis or Occlusion N/A